Renomune S 360 mg contains mycophenolic acid, a key immunosuppressive medication used to help prevent organ rejection in patients who have undergone kidney transplantation. It is an enteric-coated formulation designed to deliver the active drug in a way that reduces gastrointestinal discomfort often associated with similar agents.

This medicine is typically prescribed alongside other immunosuppressants such as tacrolimus or cyclosporine and corticosteroids, forming a protective shield that helps the body accept the transplanted organ.

Mechanism of Action

Mycophenolic acid acts by selectively inhibiting an enzyme called inosine monophosphate dehydrogenase. This enzyme is essential for the proliferation of T and B lymphocytes, which are key components of the immune response. By targeting this pathway, the drug suppresses the activity of the immune system, specifically preventing it from attacking the transplanted organ.

Unlike general immune suppressants, mycophenolic acid has a more targeted effect, which helps reduce the risk of broad immune suppression and its complications.

Therapeutic Uses

Renomune S is primarily used for:

• Prophylaxis of organ rejection in adult patients receiving a kidney transplant

• It may also be considered in other types of organ transplantation such as heart or liver, under specialist guidance

The delayed-release formulation offers improved tolerability, especially in patients who have experienced gastrointestinal issues with other formulations like mycophenolate mofetil.

Adverse Effects

While effective, Renomune S may be associated with some side effects, many of which are dose-related and require regular monitoring.

Common side effects include:

• Diarrhea or nausea

• Headache or fatigue

• Abdominal pain

• Increased susceptibility to infections such as colds or urinary tract infections